Cipla faces challenges of slow growth, drug launch; analysts slash target

Quick Summary:

Analysts at Nuvama Institutional Equities said if this challenge persists till Q3FY25 then their FY27 estimates for the company could be at risk.

The pharmaceutical company is facing a temporary supply glitch in drug Lanreotide as its product partner is enhancing capacity.

Revenue from product sales rose by 5.6 per cent to Rs 6,961 crore, compared to Rs 6,589 crore a year earlier.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: IndiaChina

Topics: Sensex Stock market Cipla news Cipla share price today Buzzing stocks Cipla q2 Nifty Cipla share price Cipla q2 results Market Cipla

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-10-30 @ 09:44:59 (2 days ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 649 words

Reading Time: 4 minutes read

Sentences: 24 lines

Sentence Length: 28 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 23334867

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 233 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 3 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions